Anthrax immune globulin intravenous (human) - Biologic Drug Details

Summary for anthrax immune globulin intravenous (human)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for anthrax immune globulin intravenous (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for anthrax immune globulin intravenous (human) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emergent Biosolutions Canada Inc.	ANTHRASIL	anthrax immune globulin intravenous (human)	Injection	125562	6,979,444	2023-07-22	DrugPatentWatch analysis and company disclosures
Emergent Biosolutions Canada Inc.	ANTHRASIL	anthrax immune globulin intravenous (human)	Injection	125562	7,208,160	2023-08-26	DrugPatentWatch analysis and company disclosures
Emergent Biosolutions Canada Inc.	ANTHRASIL	anthrax immune globulin intravenous (human)	Injection	125562	7,279,170	2026-06-22	DrugPatentWatch analysis and company disclosures
Emergent Biosolutions Canada Inc.	ANTHRASIL	anthrax immune globulin intravenous (human)	Injection	125562	7,651,702	2025-05-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for anthrax immune globulin intravenous (human) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for anthrax immune globulin intravenous (human)

Country	Patent Number	Estimated Expiration
United Kingdom	0713652
European Patent Office	2327724
Israel	176595
Mexico	2009001829

Market Dynamics and Financial Trajectory of Anthrax Immune Globulin Intravenous (Human)

Last updated: October 13, 2025

Introduction

Anthrax immune globulin intravenous (human) (AIGIV) is a critical biomedical asset developed to treat anthrax infections, primarily providing passive immunity in cases of bioterrorism or outbreak scenarios. As a specialized biologic therapeutic, AIGIV occupies a niche within biodefense and infectious disease markets, characterized by unique market dynamics driven by regulatory, tactical, and geopolitical factors. This report analyzes the current market landscape, anticipated growth trajectories, key financial considerations, and strategic implications for stakeholders involved in AIGIV.

---

Market Overview

Biodefense Market Context

Anthrax, caused by Bacillus anthracis, presents a dual threat: naturally occurring infections and potential use as a bioweapon. The biodefense sector, including government agencies such as the US CDC and BARDA, invests heavily in countermeasures like AIGIV, shaping market demand primarily through public-sector procurement and stockpiling programs.

Product Development and Regulatory Status

AIGIV received FDA approval in 2015 ([2]), marking it as one of the few approved therapeutics tailored for anthrax. The drug is manufactured by CSL Behring, leveraging plasma-derived immunoglobulin technology. Its approval was driven by the need for rapid, scalable, and effective treatment options during biothreat emergencies.

---

Market Drivers

Government and Defense Procurement

The U.S. government remains the dominant purchaser of AIGIV, investing in strategic stockpiles to ensure readiness against bioweapons and outbreaks ([3]). Contracts with BARDA and other agencies are pivotal, often dictating manufacturing volumes and pricing structures.

Biodefense Budget Allocations

Federal budgets for biodefense continue to expand, particularly in national security contexts. The Biomedical Advanced Research and Development Authority (BARDA) allocated over $100 million for anthrax countermeasures in recent fiscal years ([4]). Such allocations directly influence AIGIV's market size and growth potential.

Biothreat Perception and Stockpiling

Evolving threat landscapes—such as increased bioterrorism apprehensions—drive periodic government initiatives to update or bolster stockpiles. The National Institute of Allergy and Infectious Diseases (NIAID) emphasizes preparedness, potentially impacting future demand cycles for AIGIV.

Limited Market Competition

While other anthrax treatments exist, such as anthrax antitoxins and antibiotics, AIGIV is unique in being FDA-approved for post-exposure prophylaxis and treatment, with few direct competitors. Manufacturers of investigational products or biosimilar candidates face regulatory and scientific barriers in this niche.

---

Market Challenges and Limitations

Low Commercial Demand

Unlike blockbuster biologics, AIGIV's demand predominantly depends on government stockpiling and outbreak response. Its market volume is inherently limited, constricted by the rarity of incidents requiring deployment.

Cost and Pricing Dynamics

High production costs associated with plasma derivatives, coupled with the small market size, lead to premium pricing. Public payers and governmental agencies negotiate pricing, often constraining profitability and limiting market expansion.

Regulatory and Manufacturing Complexities

Plasma-derived biologics face stringent manufacturing standards, including plasma sourcing, pathogen reduction, and quality controls. These processes increase costs and pose risks related to supply chain disruptions.

---

Financial Trajectory and Investment Outlook

Historical Revenue and Funding Patterns

Since FDA approval, AIGIV's revenue has been largely driven by government procurement contracts. The product's sales are episodic, aligned with stockpile investments rather than steady commercial demand ([5]).

Future Revenue Projections

Projections suggest modest growth within the biodefense sector, contingent upon increased federal funding and preparedness initiatives. The annual procurement volume could grow marginally if biodefense budgets expand further, especially in response to emerging biothreats or geopolitical tensions.

Investment Considerations

Investors face high barriers due to the product's niche focus, reliance on government contracts, and limited commercial viability in unrelated markets. However, increased biodefense spending and advances in plasma technologies could provide opportunities for manufacturers and stakeholders capable of scaling production efficiently.

Potential for Broader Applications

While primarily tailored for anthrax, future research might explore expanded indications or recombinant alternatives, which could alter the financial landscape and growth prospects.

---

Strategic Implications

Stakeholder Positioning

Manufacturers and investors should monitor legislative and policy shifts that influence biodefense funding. Engaging with government agencies and maintaining compliance with evolving regulatory frameworks is crucial for sustained market presence.

Innovation and Exit Strategies

Development of next-generation biologics with enhanced efficacy or easier manufacturing could disrupt current market dynamics. Alternatively, strategic acquisitions or partnerships could streamline supply chains and reduce costs.

Global Market Opportunities

While current demand is predominantly North American and allied nations' stockpiling, expanding into international biodefense programs could unlock future revenue streams, subject to regulatory and political considerations.

---

Conclusion

The market landscape for anthrax immune globulin intravenous (human) remains characterized by a niche, government-driven demand with limited commercialization. Its financial trajectory is linked directly to biodefense budgets and strategic stockpiling policies. Despite limited near-term revenue growth prospects, the product holds critical importance within national security frameworks, presenting opportunities for sustained investment and development aligned with evolving biothreat scenarios.

---

Key Takeaways

• Market is predominantly driven by government contracts and biodefense budgets, with limited commercial demand.
• Regulatory approval in 2015 cemented AIGIV’s role as a critical biotherapeutic, but supply remains constrained by high manufacturing costs.
• Future growth hinges on increased biodefense spending and international expansion potential, though these are uncertain.
• Product reliance on plasma sources introduces supply and cost volatility, necessitating strategic planning.
• Innovation in biologic manufacturing or broader applications could unlock new revenue streams, but current market size restricts substantial profitability.

---

FAQs

1. What are the primary drivers of demand for anthrax immune globulin intravenous?
Demand is driven mainly by government agencies' stockpiling efforts for biodefense preparedness, with procurement linked to national security initiatives and outbreak management plans.

2. How does regulatory approval impact the market for AIGIV?
FDA approval in 2015 established AIGIV as an authorized treatment, enabling official procurement and fostering governmental stockpiling, although it does not induce broad commercial sales beyond government contracts.

3. What are the main challenges facing the commercialization of AIGIV?
Key challenges include limited demand due to the rarity of threats, high manufacturing costs of plasma-derived biologics, and regulatory complexities associated with plasma sourcing and product safety.

4. Could technological advances expand the market for AIGIV?
Yes, developments such as recombinant biologics or biosimilars could reduce costs and broaden applications, potentially increasing demand beyond current government procurement levels.

5. What is the outlook for biodefense funding related to anthrax countermeasures?
Biodefense budgets are expected to remain stable or increase marginally, with continued emphasis on shoring up national preparedness, which could positively influence future procurement of AIGIV.

---

References

[1] CDC. "Biodefense and anthrax." Centers for Disease Control and Prevention, 2022.

[2] FDA. "FDA approves Anthrax Antitoxin for treatment of inhalational anthrax." U.S. Food and Drug Administration, 2015.

[3] BARDA. "Biodefense Program Funding." Department of Health & Human Services, 2022.

[4] NIAID. "Biodefense Research Funding." National Institute of Allergy and Infectious Diseases, 2022.

[5] MarketWatch. "Biodefense market analysis." 2023.